WEDNESDAY, June 18, 2025 (HealthDay News) — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives Lilly a potential new treatment for heart disease, The Wall Street Journal reported. The deal, announced June 17, includes a cash offer of $10.50 per share for all outstanding […]
The post Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug first appeared on Physician’s Weekly.
